Souhaitez-vous accéder aux communiqués récents ?

Strong cash position of CHF 124.2 million provides resources to advance pipeline of seven therapeutic and three diagnostic candidates Increased R&D investment across three pillars of...

Lausanne, Switzerland, July 10, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that seven updates...

Lausanne, Switzerland, June 28, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the...

Powerful synergies in technologies and expertise Provides AC Immune with first R&D collaboration in Asia              Lausanne, Switzerland, Hong Kong, China, May 22, 2017 - AC Immune...

Strong cash position of CHF 138.1 million provides resources to advance pipeline of seven therapeutic and three diagnostic candidates Second pivotal Phase 3 clinical trial of crenezumab -...

Piramal Imaging and AC Immune present first clinical data for tau PET-imaging tracer PI-2620 at the International Conference on Alzheimer's and Parkinson's Diseases and Related...

AC IMMUNE PROVIDES TWELVE UPDATES ON ITS PIPELINE at the International Conference on Alzheimer's and Parkinson's Diseases                           Lausanne, Switzerland, March 23, 2017 - AC...

AC IMMUNE reports Full year 2016 financial results and R&D update Strong cash position of CHF 152.2 million provides resources to advance pipeline of seven therapeutic and three...

Strong commitment to potential disease-modifying therapy New Phase 3 CREAD2 trial to investigate 750 participants Current Phase 3 CREAD1 trial of 750 participants expected to read out 2020 ...

AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB Crenezumab higher dose in CREAD Phase 3 Alzheimer's trial supported by exposure-response model Phase 1b...